Interferon regulatory factor-5-dependent CD11c⁺ macrophages contribute to the formation of rupture–prone atherosclerotic plaques

Andreas Edsfeldt, Maarten Swart, Pratibha Singh, Jiangming Sun, Jennifer E. Cole, Inhye Park, Ana Persson, Mihaela Nitulescu, Patricia Das Neves Borges, Christina Kassiteridi, Michael E. Goddard, Regent Lee, Petr Volkov, Marju Orho-Melander, Lars Maegdefessel, Jan Nilsson, Irina Udalova, Isabel Goncalves, and Claudia Monaco

1Department of Clinical Sciences, Clinical Research Center, Lund University, Malmö, Sweden; 2Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden; 3Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Headington, Oxford, UK; 4Wallenberg Center for Molecular Medicine, Lund University, Malmö, Sweden; 5Department of Medicine, Karolinska Institute, Stockholm, Sweden; 6Department of Vascular and Endovascular Surgery, Technical University Munich and DZHK Partner Site Munich, Munich, Germany; and 7Nuffield Department of Surgical Sciences, Oxford, University of Oxford

Received 24 May 2021; revised 28 December 2021; accepted 29 December 2021

Aims
Inflammation is a key factor in atherosclerosis. The transcription factor interferon regulatory factor-5 (IRF5) drives macrophages towards a pro-inflammatory state. We investigated the role of IRF5 in human atherosclerosis and plaque stability.

Methods and results
Bulk RNA sequencing from the Carotid Plaque Imaging Project biobank were used to mine associations between major macrophage associated genes and transcription factors and human symptomatic carotid disease. Immunohistochemistry, proximity extension assays, and Helios cytometry by time of flight (CyTOF) were used for validation. The effect of IRF5 deficiency on carotid plaque phenotype and rupture in ApoE⁻/⁻ mice was studied in an inducible model of plaque rupture. Interferon regulatory factor-5 and ITGAX/CD11c were identified as the macrophage associated genes with the strongest associations with symptomatic carotid disease. Expression of IRF5 and ITGAX/CD11c correlated with the vulnerability index, pro-inflammatory plaque cytokine levels, necrotic core area, and with each other. Macrophages were the predominant CD11c⁺ expressing cells in the plaque by CyTOF and immunohistochemistry. Interferon regulatory factor-5 immunopositive areas were predominantly found within CD11c⁺ areas with a predilection for the shoulder region, the area of the human plaque most prone to rupture. Accordingly, an inducible plaque rupture model of ApoE⁻/⁻Irf5⁻/⁻ mice had significantly lower frequencies of carotid plaque ruptures, smaller necrotic cores, and less CD11c⁺ macrophages than their IRF5-competent counterparts.

Conclusion
Using complementary evidence from data from human carotid endarterectomies and a murine model of inducible rupture of carotid artery plaque in IRF5-deficient mice, we demonstrate a mechanistic link between the pro-inflammatory transcription factor IRF5, macrophage phenotype, plaque inflammation, and its vulnerability to rupture.

* Corresponding author. Tel: +44 1865 612636, Fax: +44 1865 612601, Email: claudia.monaco@kennedy.ox.ac.uk
† These authors contributed equally to the study.
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Key question
The transcription factor interferon regulatory factor-5 (IRF5) is a master regulator of macrophage activation that has been shown to have a role in murine atherogenesis. Its role in human atherosclerosis and its complications is unknown.

Key finding
Interferon regulatory factor-5 is linked to plaque vulnerability and symptoms in human carotid endarterectomies. In a murine model of inducible carotid artery plaque rupture, IRF5 drives plaque rupture. Interferon regulatory factor-5 modulates macrophage phenotype and it colocalises with CD11c+ macrophages at the plaque shoulder.

Take-home message
We demonstrate a mechanistic link between the IRF5, plaque macrophages, and plaque vulnerability to rupture. Interferon regulatory factor-5 is a potential candidate therapeutic target in human atherosclerosis.

Structured Graphical Abstract
Macrophages perform both pro- and anti-atherogenic functions depending on their transcriptional status and activation. Using human carotid endarterectomies and a murine model of inducible rupture of carotid plaque, we show that the transcription factor interferon regulatory factor-5 (IRF5) promotes macrophage activation with the production of chemokines CCL2 and CCL4, and the expression of the integrin CD11c, while it disables the production of proteins required for the uptake of apoptotic cells within the plaque (efferocytosis) such as MFEG8 and the integrin ITGB3. In doing so, IRF5 promotes inflammation and increases the necrotic core size enhancing plaque vulnerability to rupture. MFEG8, Milk fat globule—epidermal growth factor—factor VIII; CCL2, C–C motif chemokine ligand 2; CCL4, C–C motif chemokine ligand 4; ITGB3, Integrin subunit beta 3.

Keywords
IRF5 • Macrophages • Atherosclerosis • Plaque rupture

Translational perspective
Macrophages perform both pro- and anti-atherogenic functions depending on their programming. Rewiring macrophage transcriptional states is an attractive therapeutic strategy for cardiovascular disease. The transcription factor interferon regulatory factor-5 (IRF5) is a master regulator of macrophage activation, important in murine atherogenesis. Its role in human atherosclerosis and its complications are unknown. Using human carotid endarterectomies and a murine model of inducible rupture of carotid plaque, we here demonstrate that IRF5 has a role in plaque vulnerability and rupture. Our study indicates that IRF5 is a candidate therapeutic target to lower the risk of plaque rupture by reducing macrophage activation and plaque inflammation.
Introduction

Ischaemic stroke is one of the dominant causes of severe morbidity and premature death. Rupture of an atherosclerotic plaque is considered to be one of its major underlying causes. Lipoprotein retention and inflammation in the arterial wall both contribute to atherosclerotic plaque formation. The formation of rupture-prone plaques, so-called vulnerable plaques, is the result of cell death, impaired efferocytosis, and degradation of the stabilizing fibrous cap. Activation of the immune system not only contributes to atherosclerosis but also to vulnerable plaque biology. Macrophages are key players in cardiovascular disease (CVD) and their polarization states have a role in atherogenesis. Different stimuli and transcription factors have been shown to regulate macrophage states in vitro and in murine models of atherogenesis. Yet, the transcription factors that drive macrophage activation in the human plaque and its rupture remain to be identified.

Interferon regulatory factor 5 (IRF5) is a master regulator of pro-inflammatory macrophages in mouse and human. We previously showed, in ApoE−/− mice on a chow diet, that IRF5 drives atherogenesis and the formation of the necrotic core by impairing macrophage efferocytosis capacity. Conditional myeloid deficiency of IRF5 phenocopied the effect on murine atherosclerotic lesion formation and macrophage polarization, providing further insight on the importance of IRF5 in lesional macrophage proliferation and foam cell formation in ApoE−/− mice with a high-cholesterol diet. Evidence for a role of IRF5 in human atherosclerosis and plaque rupture is so far lacking. Here, we show that IRF5 and CD11c expression is linked to symptomatic and vulnerable carotid plaques in humans, and that IRF5 drives pro-inflammatory CD11c+ macrophages and inducible plaque rupture in ApoE−/− mice, demonstrating IRF5 as a candidate therapeutic target in human atherosclerosis.

Methods

A fully detailed description can be found as Supplementary material online.

Carotid plaque cohort

Human atherosclerotic carotid plaques were obtained from the Carotid Plaque Imaging Project (CPIP) biobank to study IRF5 and CD11c expression. All patients included in the CPIP cohort gave their informed consent to participate in the study. The study was approved by the ethical review board at Lund University and follows the declaration of Helsinki.

Plaques used included in the study were either associated with symptoms (stroke, transient ischaemic attack, or amaurosis fugax) with a degree of stenosis >70% (assessed by duplex ultrasound) or asymptomatic with a degree of stenosis >80%. All patients included were examined by a neurologist prior to surgery.

Clinical characteristics of the cohort, including information regarding smoking, hypertension (systolic blood pressure >140 mmHg), and the use of statins were recorded at inclusion. Plasma samples to assay glycated haemoglobin (HbA1c), creatinine, high-sensitivity C-reactive protein (hsCRP), and circulating lipoproteins were collected the day before surgery.

All collected plaque specimens were immediately snap frozen after surgical removal. A 1 mm fragment from the most stenotic region of the plaque was kept for histological analysis and the rest of the plaque was homogenized.

Human plaque RNA sequencing

Expression values of macrophage associated genes and transcription factors were evaluated from the global transcriptome RNA sequencing data of 60 carotid plaque samples.

Human carotid plaque histology and immunofluorescence

The 1 mm segment from the most stenotic part of the plaque was cryo-sectioned into 8 µm sections. Sections were then stained for neutral lipids (Oil Red O), macrophages (CD68), smooth muscle cells (α-actin), intra-plaque haemorrhage (glycoprotein A/CD235), and collagen (Russell-Movat pentachrome).

Vulnerability index was calculated as a ratio between the sum of lipids (Oil red O, % plaque area), macrophages (CD68, % plaque area), and intra-plaque haemorrhage (glycoprotein A, % plaque area) divided by the sum of smooth muscle cells (α-actin, % plaque area) and collagen (Movat pentachrome, % plaque area).

Immunofluorescence staining was performed on 8 µm carotid sections embedded in optimal cutting temperature (OCT) compound using a cocktail of anti-CD11c (Abcam, ab11029) and anti-CD68 (cell signalling technology, clone D4B9C, #764375) antibodies.

Mass cytometry

Carotid endarterectomies from patients undergoing surgery for carotid artery disease for mass cytometry were obtained at John Radcliff Hospital, Oxford, UK. The protocol was approved by the Research Ethics Committee. Tissues were enzymatically digested and single cell suspension was generated as previously described.

All directly conjugated antibodies were purchased from Fluidigm or conjugated in-house using MaxPar X8 Polymer Kits (Fluidigm) according to the manufacturer’s instructions (listed in Supplementary material online, Table S1). Samples were stained with rhodium DNA intercalator (Fluidigm) as a viability dye and Fc receptors were blocked (BD Biosciences) before cells were stained with the antibody mixture for 30 min at 4°C. The cells were then washed and incubated with Iridium DNA intercalator (Fluidigm) in Maxpar fix and perm buffer (Fluidigm) overnight at 4°C. Prior to acquisition, cells were washed with water (Fluidigm) and acquired on a Helios mass cytometer (Fluidigm). Data in the fcs files format were uploaded to Cytobank (www.cytobank.org) for gating and analysis using the automated dimensionality reduction algorithm viSNE. The gating strategy consisted of sequential gating for intact single cells using the iridium DNA intercalator, removal of the normalization beads, and gating for cell viability using the rhodium DNA intercalator. CD45+ cells were gated based on expression of CD45.

Mouse model

ApoE−/−/IRF5−/− mice were generated by breeding ApoE−/− mice (C57BL/6 background from Charles River Laboratories) in-house with IRF5−/− mice on a C57BL/6 background. All mice were studied according to institutional guidelines and to UK Home Office regulations. Only male mice were used and all mice were negative for the Dock2 mutation. Mice were fed chow diet and were housed under specific pathogen-free conditions. A surgical model combining carotid artery ligation and placement of a shear stress modifying cast was used.
to study effect of IRF depletion in inducible plaque ruptures (Supplementary material online, Figure S1).

**Statistical analysis**

CD11c and IRF5 plaque areas were non-normally distributed whereas ITGAX and IRF5 gene expression were normally distributed according to Shapiro–Wilk test for normality. Variables are presented as median and interquartile range (IQR) or mean and standard deviation (SD) depending on distribution. Mann–Whitney U test (continuous data), Student’s t-test (continuous data), and $\chi^2$ test (categorical data) were used for two group comparisons. Spearman’s rho and Pearson’s correlation coefficient were used for correlation analyses.

**Data availability**

The data underlying this article will be shared on reasonable request and in compliance with the appropriate general data protection regulation (GDPR) regulations.

**Results**

**Interferon regulatory factor 5 and CD11c gene expression are associated with symptomatic human carotid plaques**

RNA sequencing was performed on RNA isolated on the most stenotic region of human atherosclerotic carotid plaques from the CPIP cohort. Patient clinical characteristics are presented in Table 1.

Amongst 29 commonly described macrophage associated markers and transcription factors, we set to identify the ones that could separate symptomatic (symptoms <31 days prior to surgery, $n = 24$) from asymptomatic plaques ($n = 23$) using the orthogonal projections to latent structures discriminant analysis (OPLS-DA) method. The OPLS-DA analysis revealed that symptomatic plaques were statistically distinguishable from asymptomatic based on selected markers ($R^2_Y = 0.34$, $Q^2_Y = 0.2$; CV ANOVA $P = 0.008$). CD11c (ITGAX) and IRF5 were identified to be the strongest contributors to the separation (ranked highest on VIP score, Figure 1A). Gene expression levels of IRF5 and ITGAX were also significantly higher in symptomatic compared with asymptomatic plaques [7.3 (SD 0.6) vs. 6.8 (SD 0.9) log2 normalized counts, $P = 0.033$ and 10.6 (SD 0.8) vs. 9.7 (SD 1.3) log2 normalized counts, $P = 0.007$; $n = 60$; Figure 1B]. No associations between IRF5 or CD11c protein expression and gender, age, body mass index, HbA1c, diabetes, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides, hsCRP, creatinine, or medications (lipid-lowering or anti-hypertensive) were identified.

**Interferon regulatory factor 5 and ITGAX were co-expressed in a gene cluster that is associated with symptomatic status**

Based on the RNA-seq data, network clustering was performed. Six gene modules were identified (Supplementary material...)}
Figure 1 ITGAX (CD11c) gene expression and CD11c plaque area are associated with a vulnerable plaque phenotype and symptomatic carotid plaques in humans. (A) Using an OPLS-DA analysis, IRF5 and ITGAX (CD11c) were identified as the myeloid cell surface marker and transcription factor and with the largest impact on separating symptomatic (<31 days prior to surgery) plaques from asymptomatic plaques. RNAseq data from 47 human carotid plaques (24 symptomatic and 23 asymptomatic). Blue indicates asymptomatic and red indicates symptomatic. (B) Human plaque gene expression levels of IRF5 and ITGAX (CD11c) were also significantly increased in plaques associated with symptoms within 31 days prior to surgery compared with asymptomatic plaques. Lines indicate mean levels, each dot represents an individual value (n = 60, 34 symptomatic and 26 asymptomatic). (C) CD11c+ but not IRF5+ plaque area, as assessed by immunohistochemistry, was increased in symptomatic carotid plaques. Lines indicate median levels, each dot represents an individual value (n = 62, 35 symptomatic <31 days prior to surgery and 27 asymptomatic). Data are presented as % of total plaque area. (D) OPLS-DA analysis identified ITGAX as the myeloid cell gene with the largest impact on separating plaques with a vulnerability index above median from plaques with a vulnerability index below median (n = 47, 24 symptomatic and 23 asymptomatic). Blue indicates less than median vulnerability index and red indicates greater than median vulnerability index. (E) IRF5 and CD11c plaque areas are increased in plaques with a high (above median, n = 31) vulnerability index compared with plaques with a low vulnerability index (below median, n = 31). Mann–Whitney U tests were used. (F) Plaque area stained positive for CD11c and IRF5 correlated with the calculated vulnerability index (n = 62). Spearman test was used for the correlation analysis. CD11c, cluster of differentiation 11c; IRF5, interferon regulatory factor 5.
Online, Figure S2A). IRFS and ITGAX were found in the blue module which comprises of 482 genes in total. Interestingly, the first principal component of the gene expression of blue module showed positive correlation with symptomatic status \((r=0.39, P=0.002, \text{Supplementary material online, Figure S2B})\). Within the module, ITGAX and IRFS showed high intra-modular connectivity and relatively high gene significance in the association with symptomatic status and (Supplementary material online, Figure S2C). This gene cluster enriched in ‘proteins involved in non-alcoholic fatty liver disease’ \((P=6.9 \times 10^{-11})\) and ‘proteins involved in atherosclerosis’ \((P=1.7 \times 10^{-3})\) whereas IRFS was absent in the enriched term. The top enriched pathway was ‘dendritic cells function in atherosclerosis’ \((P=0.002)\) when IRFS was present.

### Interferon regulatory factor 5 and CD11c are associated with a vulnerable plaque phenotype in humans

Next, tissue sections from the most stenotic region of 62 carotid plaques (27 asymptomatic and 35 with symptoms ≤31 days prior to surgery, clinical characteristics are presented in Table 2) were stained for CD11c and IRFS. Plaque area stained positive for CD11c was significantly higher in the symptomatic than the asymptomatic plaques \((0.7 \text{ IQR} 0.53 – 1.54\%) \text{ vs. } 0.2 \text{ (IQR} 0 – 0.9\%) \text{ of total plaque area, } P=0.004, \text{ Figure 1C}) whereas no significant difference was identified in the area positive for IRFS \((0.24 \text{ (IQR} 0.06 – 1.45\%) \text{ vs. } 0.2 \text{ (IQR} 0.01 – 1.0\%) \text{ of total plaque area, } P=0.32)\).

We next sought to explore if IRFS and CD11c were associated with the rupture-prone or vulnerable plaque phenotype. \(^3\) The human carotid plaques were classified into high or low vulnerability index based on their histological characteristics assessed on adjacent sections as previously described. \(^4\) In short, the sum of plaque area stained positive for macrophages (CD68), intra-plaque haemorrhage (glycophorin A), and lipids (Oil red O) was divided by the sum of plaque area stained positive for collagen (Movat pentachrome) and vascular smooth muscle cells (α-actin; \text{Supplementary material online, Figure S3}). Using an OPLS-DA analysis on the gene expression data, we identified the transcription factors and macrophege markers that had the greatest influence on separating plaques with a high vulnerability index from plaques with a low vulnerability index (above or below median; \(R^2_Y=0.27, Q^2_Y=0.18; P=0.018\)). Importantly, IRFS and CD11c were again identified to be amongst the strongest contributors for separating plaques with a more vulnerable plaque phenotype from stable plaques (ranked amongst top VIP scorers; Figure 1D). In line with this, CD11c and IRFS immunopositive plaque areas were greater in plaques with a vulnerability index above median \([0.8 \text{ (IQR} 0.06 – 1.7\%) \text{ vs. } 0.15 \text{ (IQR} 0.01 – 0.43\%); P=0.008 \text{ and } 0.9 \text{ (IQR} 0.5 – 1.4\%) \text{ vs. } 0.2 \text{ (IQR} 0.0 – 1.2\%); P=0.017; \text{ Figure 1E, n=47})\). Interferon regulatory factor 5 and CD11c immunopositive plaque areas also correlated positively with the vulnerability index \((r=0.26, P=0.049 \text{ and } r=0.45, P=5 \times 10^{-4})\), respectively; Figure 1F).

### Interferon regulatory factor 5 is associated with CD11c expression

To explore if CD11c expression was associated with IRFS in human carotid atherosclerosis we sought to identify whether IRFS gene expression and plaque area correlated with CD11c gene

| Clinical characteristics of the 62 patients which plaques were used for immunohistochemical analyses of IRF5 and CD11c | Asymptomatic (n = 27) | Symptomatic (n = 35) | P-value |
|---|---|---|---|
| Male sex | 67% | 63% | 0.8 |
| Age, years, median (IQR) | 68 (63–70) | 71 (64–78) | 0.04 |
| Diabetes | 26% | 40% | 0.25 |
| BMI, kg/m², mean (IQR) | 27 (24–29) | 27 (24–30) | 0.57 |
| Current smoker | 52% | 23% | 0.06 |
| Hypertension | 78% | 77% | 0.9 |
| Medication | | | |
| Anti-hypertensive | 81% | 89% | 0.4 |
| Statins | 93% | 86% | 0.4 |
| Laboratory parameters, median (IQR) | | | |
| Total cholesterol (mmol/L) | 4.1 (3.4–5.3) | 4.2 (3.5–5.6) | 0.8 |
| LDL (mmol/L) | 2.3 (1.9–3.2) | 2.7 (2.0–3.9) | 0.4 |
| HDL (mmol/L) | 0.9 (0.8–1.4) | 1.1 (0.8–1.2) | 0.9 |
| Triglycerides (mmol/L) | 1.3 (0.9–2.2) | 1.7 (1.1–2.3) | 0.3 |
| Creatinine (mmol/L) | 85 (74–94) | 91 (70–107) | 0.65 |
| hsCRP (mg/L) | 4.1 (1.8–6.8) | 4.5 (1.8–6.7) | 0.9 |

Mann–Whitney test or \(\chi^2\) test for categorical data.

IQR, interquartile range; BMI, body mass index; LDL, low-density lipoproteins; HDL, high-density lipoproteins; hsCRP, high-sensitivity C-reactive protein. Symptomatic means patients suffering from a transient ischaemic attack, stroke of amaurosis fugax ≤31 days prior to surgery.
expression. Importantly, plaque gene expression of IRF5 correlated strongly with CD11c gene expression levels \((r = 0.7, P = 7.46 \times 10^{-10}; \text{Figure 2A})\). Fittingly, IRF5 immunopositive plaque area correlated to CD11c immunopositive plaque area \((r = 0.35, P = 0.005; \text{Figure 2B})\) and IRF5 protein expression co-localized with CD11c protein expression in the plaque \((\text{Figure 2C and D}); \text{isotype controls presented in Supplementary material online, Figure S4})\). Importantly, co-localization of IRF5 and CD11c were identified in close proximity to the core region as well as in the shoulder region. The most evident co-localization was identified in the shoulder regions of the plaques \((\text{Figure 2D})\).
CD11c is predominantly expressed by macrophages in human carotid atherosclerosis

Next, the immune landscape in human atherosclerotic plaques was characterized using mass cytometry to elucidate which cell types predominantly express CD11c. Data were analysed using an unbiased dimensionality reduction algorithm, t-distributed stochastic neighbor embedding (tSNE) on live CD45+ cells and single cells were clustered according to shared marker expression \( (n = 4) \). These analyses revealed 11 distinct clusters (Figure 3A) including macrophage and dendritic cell (DC) populations. Specific cell clusters were identified based on the expression of the different markers per cluster as shown in the heatmap (Figure 3B). T cells, CD4 and CD8T cells constitute 50% of plaque CD45+ cells. Myeloid cells (macrophages and DCs) come second comprising 22% of all CD45+ cells.
cells (Figure 3C and Supplementary material online, Figure S5). CD11c is usually considered a marker for DCs; however, it is also expressed by macrophages.\textsuperscript{15} Indeed, along with DCs, macrophages in human atherosclerotic plaques express high levels of CD11c as shown in the overlay plots (Figure 3A) and in the heatmap (Figure 3B). In fact, most of the CD11c-expressing cells in the human atherosclerotic plaques were identifiable as macrophages (85% vs. 15%, Figure 3D). Immunofluorescence triple staining on human plaque tissue confirmed that the majority of CD11c\textsuperscript{+} cells were also CD68 positive (Figure 3E).

Interferon regulatory factor 5 regulates macrophage phenotype and function contributing to plaque inflammation and increased necrotic core size in human atherosclerosis

Interferon regulatory factor 5 and ITGAX show strong associations with gene levels of macrophage markers in our plaque RNA sequencing analysis including CD68, CSF1R, FCGR1A, and ITGAX ($r = 0.37$–0.85 and adjusted $q$-value < 0.01 (according to the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli; Supplementary material online, Figure S6). No correlation was found with DC markers. Amongst T cell markers, CD4 expression, shared by human T cells and macrophages, also correlated with IRF5 and ITGAX expression ($r = 0.67$, adjusted $q < 0.01$ and $r = 0.85$, adjusted $q < 0.01$, respectively). Due lack of association with other T cell markers, the association with CD4 was likely driven by the presence of CD4\textsuperscript{+} plaque macrophages.\textsuperscript{16} Both IRF5 and ITGAX expression correlated negatively to smooth muscle cell lineage markers, ACTA2 and MYH11 ($r = -0.51$ to $-0.70$ and adjusted $q$-value < 0.01 (according to the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli) for all). In line with these findings, no clear overlap of IRF5 and $\alpha$-actin positive areas were detected (Supplementary material online, Figure S7).

Next, we sought to explore whether the expression of IRF5 and CD11c was associated with plaque inflammation and size of the necrotic core in human atherosclerosis. First, we assessed necrotic core (acellullar and non-fibrotic areas) size in the human carotid plaques using Movat pentachrome (Figure 4A). A clear positive correlation between CD11c protein expression and necrotic core size was also identified in the human plaques ($r = 0.5, P = 0.0001$; Figure 4B). Interferon regulatory factor-5 induced CD11c\textsuperscript{+} macrophages have been shown to reduce the efferocytosis capacity by down-regulating the Mfge8-\alpha\beta3 integrin pathway in mice.\textsuperscript{10} In line with the previous murine study, we identified strong inverse correlations of IRF5 and ITGAX gene expression with Mfge8 expression ($r = -0.6, P = 3.1 \times 10^{-7}$ and $r = -0.57, P = 2 \times 10^{-6}$, respectively; Figure 4C and D). No associations with ITGB3 was identified, possibly due to the ITGB3 expression not being restricted to macrophages.

To test if IRF5 activation affects Mfge8 expression, THP-1 cells were matured into macrophages using PMA in vitro. IRF5 was then silenced using siRNA. Interestingly, expression of both ITGB3 and Mfge8 were significantly increased upon IRF5 silencing (Figure 4E).

Next, to explore the association of IRF5 and CD11c with plaque inflammation gene expression levels and plaque tissue homogenate protein levels of IL-6, CCL-3, CCL-4, IL-10, and CCL-2 were assessed. Plaque protein levels of CCL-3, CCL-4, and CCL-2 were all found to correlate with CD11c\textsuperscript{+} and plaque area whereas IRF5\textsuperscript{+} plaque area only correlated significantly with CCL-3 protein levels (Figure 4F). Plaque gene expression levels of IRF5 and ITGAX correlated with CCL-3, CCL-4, and CCL-2 gene expression [significant gene correlations had calculated q-values $\leq 0.01$ (FDR 1%), according to the two-stage step-up method of Benjamini, Krieger, and Yekutieli; correlations coefficients are shown in Figure 4F]. THP-1 derived macrophages were polarized into a pro-inflammatory phenotype and transfected with IRF5 siRNA or left untreated. In line with the correlations identified in the human plaque tissue, treated with IRF5 siRNA had significantly lower gene expression levels of ITGAX, CCL-4, and CCL-2 (Figure 4G). Finally, using adenovirus transfection in isolated human atheroma plaque cell cultures we assessed if IRF5 overexpression affects the inflammatory activity. In line with our siRNA experiments, the overexpression of IRF5 human plaque cells significantly increased the release of IL-6 into plaque cell culture supernatants (Figure 4H).

Interferon regulatory factor 5 deficiency reduces the frequency of plaque ruptures in mice

As IRF5 and CD11c were strongly associated with plaque rupture in human atherosclerosis, we aimed to explore whether IRF5 deficiency would reduce plaque rupture frequency. To do so, a surgical model combining carotid artery ligation with a shear stress modifying cast was used (Supplementary material online, Figure S1). Upon the ligation and collar placement we confirmed continuous blood flow using computed tomography with arterial contrast agent as seen in Figure 5A.

To identify plaque ruptures (a disruption of the endothelium with infiltrating blood and a luminal thrombus), which commonly occurred between the cast and the ligation (Figure 5B), all common carotid arteries were sectioned and every 50 $\mu$m stained with haematoxylin and eosin (H&E). No significant difference in plaque size was identified comparing ApoE\textsuperscript{+/−} and ApoE\textsuperscript{−/−} IRF5\textsuperscript{−/−} (Figure 5C). Plaque ruptures were identified in 12 out of 33 (36%). When comparing the frequency of plaque ruptures in ApoE\textsuperscript{+/−} and ApoE\textsuperscript{−/−} IRF5\textsuperscript{−/−} mice, the frequency of plaque ruptures was significantly reduced in the IRF5-deficient mice (3 of 16 vs. 9 of 17, $P = 0.04$; Figure 5D).

Interferon regulatory factor 5 deficiency reduces CD11c positive plaque area and the number of CD11c\textsuperscript{+} macrophages

Next, we assessed plaque area of necrotic core (H&E), CD68, CD11c, CD206, collagen (Picrosirius Red), and TUNEL to identify plaque phenotype changes associated with IRF5 deficiency. Importantly, necrotic core and CD11c plaque area
Figure 4. CD11c is associated with necrotic core area and reduced gene expression levels of Milk Fat Globule—Epidermal growth factor—factor VIII (MFGE8). (A) Movat pentachrome was used to identify necrotic core areas (acellular non-fibrotic tissue). Core area is marked by red-dotted line. Scale bar 1 mm (n = 57). (B) Human plaque necrotic core area correlate strongly with CD11c plaque area (n = 57). Data are presented as % of total plaque area. Spearman rank correlation test was used. (C,D) MFGE8 gene expression levels correlate inversely to plaque gene expression levels of IRF5 and ITGAX (CD11c). Data are presented as normalized counts. Spearman’s rank correlation coefficient was used (n = 60). Red indicates symptomatic patients and blue indicates asymptomatic patients. (E) Gene expression levels of MFGE8 and ITGB3 were up-regulated in THP-1 PMA matured macrophages upon IRF5 silencing, n = 11–12. Mann–Whitney U tests were used to identify significant differences. Boxes represent median levels and bars represent interquartile range. (F) Heatmap showing correlation coefficients for CD11c and IRF5 positive plaque area, plaque tissue gene expression of ITGAX and IRF5 to plaque protein levels and plaque gene expression levels of interleukin-6 (IL6), Chemokine (C–C motif) ligand 3 (also known as macrophage inflammatory protein-1α), Chemokine ligand 4 (CCL4/macrophage inflammatory protein-1β), monocyte chemoattractant protein-1 (MCP-1/CCL2), and interleukin-10 (IL10). CD11c and IRF5 plaque area were presented as % of total plaque area. IL6, CCL3, CCL4, and MCP-1 were presented as arbitrary units/gram wet weight plaque. Interleukin-10 was presented as picogram/gram wet weight plaque. Spearman’s rho was used for correlations analyses. (G) Gene expression levels of CCL2 (MCP-1), CCL4, ITGAX (CD11c), and IRF5 were reduced by IRF5 silencing in M1 matured THP-1 cells, n = 9. Mann–Whitney U tests were used to identify significant differences. Boxes represent median levels and bars represent interquartile range. (H) IRF5 overexpression by adenovirus transfection of human plaque cells caused increasing release of IL6 into cell culture supernatants. Four replicates per condition were studied. Unpaired t-test was used to identify significant differences. siQ, silencing control.
were reduced in the IRF5−/− group [6.7 (IQR 2.1–12.3)% vs. 14.7 (IQR 10.7–20.6)% of plaque area, \( P = 0.035 \) and 5.6 (IQR 3.1–9.9)% vs. 10.05 (IQR 4.2–17.2)% plaque area \( P = 0.03 \), respectively; Figure 5E–G and Supplementary material online, Figure S8].

To confirm if the reduction in CD11c was due to a loss of CD11c+ macrophages as we previously showed, leukocytes from the anatomically closely related deep cervical lymph nodes were isolated. Using flow cytometry (gating strategy presented in Supplementary material online, Figure S9A), we identified a...
61% reduction in macrophages (CD11b+ and F4/80+; \( P = 0.006 \), Supplementary material online, Figure S9B) and a 72% reduction in CD11c+ macrophages (CD11b+; F4/80+ and CD11c+; \( P = 0.007 \), Supplementary material online, Figure S9C). No difference in CD11c+ DCs was seen (identified as CD11c+high and MHC-IIhigh; Supplementary material online, Figure S9D).

**Discussion**

The view that inflammation is a key component of atherosclerotic plaque formation, vulnerability, and rupture has gathered momentum in recent years.2–3,17,18 Macrophages are key initiators of athero-inflammation but are also crucial to the resolution stages of the inflammatory process, with their contribution depending on their state of activation.5 Rewiring macrophage transcriptional states is an attractive therapeutic strategy in CVD to prevent excess inflammation. We and others recently showed the importance of the transcription factor IRF5 in murine atherosclerosis.10,11

In the present study, we demonstrate by two complementary strands of evidence in mouse and human a direct mechanistic link between the pro-inflammatory transcription factor IRF5, macrophage activation, and atherosclerotic plaque vulnerability to rupture (Structured Graphical Abstract).

By mining the gene expression of macrophage associated markers and transcription factors in the plaque bulk RNA sequencing in the CPIP cohort, we identify IRF5 as the transcription factor with the greatest impact on differentiating symptomatic from asymptomatic carotid disease. No significant increase of IRF5 plaque immunopositive area was found in symptomatic plaques, possibly due to divergences of kinetics between RNA and protein. Considering that asymptomatic plaques can be at high risk for rupture and that the phenotype of symptomatic plaques may change due to repair processes activated upon the rupture, we used a histological vulnerability index as a marker of rupture-prone plaques. We and others have previously demonstrated the utility of this carotid vulnerability index as a composite histological score combining markers of plaque stability and vulnerability to assess an overall risk score of the plaque phenotype and predict future cardiovascular events.14,19–23 This simultaneous combination of markers has previously been used by us and others and aims to provide a global balance of plaque stability, instead of relying on single markers. Interferon regulatory factor-5 expression at the protein and gene level was significantly associated with the plaque composite vulnerability index, indicating the existence of a close correlation between unfavourable plaque composition and IRF5 expression.

In earlier studies, IRF5 was shown to have a pro-atherogenic role in mouse model of lipid-driven atherogenesis,10,11 and in the formation of plaques with a thin-cap fibroatheroma in a shear stress modulated lesion model.10 These models differ from human disease, as the atherosclerotic plaques they form, rarely rupture within the timeframe of the studies. In this manuscript, we utilized an inducible plaque rupture model where a plaque disruption occurs in 50% of the mice undergoing surgery.24–26 This surgical model leads to the formation of vulnerable and ruptured plaques with increased necrotic core size, thinned and cracked fibrous caps, and formation of a thrombus inside the lumen (Supplementary material online, Figure S10). Interferon regulatory factor-5 deficiency protected from the development of plaque rupture in this model, demonstrating that IRF5 not only drives the formation of morphologically vulnerable plaques,10 but also induces actual plaque rupture. The effect of IRF5 deficiency in preventing carotid rupture of atherosclerotic plaques in mice and the association of IRF5 expression with unfavourable vulnerability carotid plaque index in humans demonstrate that IRF5 is a candidate therapeutic target for plaque vulnerability in humans.

Traditionally, the expression of CD11c in atherosclerosis has only been studied in the context of DCs.27,28 However, CD11c is a marker shared between macrophages and DCs. Using mass cytometry in murine atherosclerosis, we have recently shown that in murine aorta, CD11c is predominantly expressed by macrophages and DCs.28 We have also shown that aortic CD11c+ macrophages are the only subset of macrophages whose representation increases during atherogenesis.29 Aortic intima resident macrophages express CD11c and have a pro-atherogenic role in murine models.30 To date, less is known regarding the cellular identity of CD11c myeloid cells in the human atherosclerotic plaque. Using cytometry by time of flight, we show that CD11c+ macrophages are the most common CD11c myeloid cells in the human plaque. This is in agreement with our histological findings showing co-localization between CD68 and CD11c in the human atherosclerotic plaque.

We have previously shown that overexpression of IRF5 in human primary macrophages leads to a pro-inflammatory ‘M1’ macrophage polarization with up-regulation of inflammatory genes.8,9 We also have demonstrated that IRF5 leads to pro-inflammatory ‘M1’ macrophage polarization in murine macrophages in vitro, and in models of atherosclerosis and arthritis.31 We showed that in mouse IRF5 drives the transcription of the Itgax gene that encodes for CD11c, and genetic deficiency of IRF5 resulted in a loss of CD11c+ intralosomal macrophages.10 In the current study, our computational analysis provides several lines of evidence that CD11c and IRF5 expression are a distinguishing feature of plaques with a high vulnerability index and/or symptomatic carotid plaques. Interferon regulatory factor-5 and CD11c are not only correlated with each other at the gene and protein level, but their expression was also positively correlated with the levels of pro-inflammatory markers. Inverse correlations between IRF5 and ITGAX with MFGE8 gene expression were identified, in agreement with our previous study where IRF5-deficient mouse macrophages had an increased efferocytic capacity through up-regulation of Mfge8 and Itgb3 (both important factors in efficient efferocytosis).10 These positive and negative associations were reproducible in vitro (Figure 4). Finally, IRF5 gene expression was significantly positively correlated with the expression levels of macrophage marker genes, but not DCs. In absence of correlations with other lymphocyte markers, correlation between the expression of IRF5 and CD4 could be due to the expression of CD4 by human plaque macrophages.16 Interestingly, strong negative correlations were observed between IRF5, ITGAX, and smooth muscle cell markers, in keeping with immunohistochemistry data (Supplementary material online, Figure S7) reinforcing the link between IRF5 and human vulnerable plaque biology. Our RNASeq and functional
data indicate that the relevance of IRF5 to human vulnerable plaque biology is linked to its ability to regulate macrophage phenotype and activation.

Consistently, in an inducible model of carotid artery plaque rupture, a reduction in necrotic core size and CD11c expression in the lesion was observed in ApoE−/−Irf5−/− mice when compared with ApoE−/− mice, without a significant effect on total CD68 or CD206 expression indicating a specific loss of CD11c expression on plaque macrophages. This loss in the plaque was mirrored by a loss of CD11c macrophages, but not DCs, in the draining deep cervical lymph nodes. The evidence that CD11c expression, macrophage content, and necrotic core plaque area are affected by prevention of IRF5 induced changes in plaque composition and macrophage phenotype. Taken together, our data demonstrate that CD11c+ macrophages are an IRF5-driven pro-inflammatory subset of macrophages that are enriched in plaques vulnerable to rupture.

The shoulder region is known to be an active area of the plaque located at the boundary between plaque and normal artery, and a common location for a rupture to occur.32 According to Richardson et al.,32 nearly two-thirds of all plaque ruptures were identified in the shoulder region which was also confirmed in an intravascular ultrasound study by Maehara et al.33 IRF5 staining was largely contained within CD11c immunopositive carotid plaque areas generally surrounding the core of the plaque with a predilection for the shoulder regions of the plaques. In concert with the evidence that IRF5 deficiency prevents plaque rupture in mice, our findings implicate IRF5 in enhanced inflammation in the shoulder region, leading to plaque rupture.

There is today no clear evidence from genome-wide association studies (GWAS) supporting the role of IRF5 in CVD. Genome-wide association studies had shown that IRF5 downstream variants were strongly associated with coronary artery disease (leading variant rs11556924, n = 1543070, P = 5.5 × 10−38; https://t2d.hugeamp.org). However, this variant was about 1 Mb far away from gene body of IRF5. Whether IRF5 played a definite causal role need further investigation, e.g. Mendelian randomization. An upstream variant rs9972727 of CD11c showed strong association with CVD (P = 1.0 × 10−11).34 Interestingly, this variant was also an eQTL SNP which regulated gene expression of CD11c (P = 9.4 × 10−207) in human blood which suggested that CD11c may be implicated in CVD.35 Yet, the lack of strong GWAS evidence does not rule out that IRF5 induced CD11c+ macrophages are important mediators in the formation of rupture-prone atherosclerotic plaques.

Our study is not without limitations. There is not a single experimental model of atherosclerosis that reproduces all facets of human CVD. The inducible plaque rupture model has been well described and used to induce plaque ruptures in mice, despite its imperfections to mimic human disease.24–26 This model could not allow the study of plaque erosion which is responsible for ~25–40% of cardiovascular complications.36–38 A second limitation of the study is that we could not identify association between risk factors such as diabetes and IRF5 or CD11c expression in the carotid plaques due to the relatively limited number of patients included. Such association was previously demonstrated in peripheral blood cells.39 The lack of associations in our study could likely be explained by the fact that the diabetes patients included in the present study had a rather good glycaemic control (median HbA1c levels 56 mmol/mol). Discrepancies in the plaque areas positive for CD11c and IRF5 immunostaining can likely be explained by the fact that IRF5 expression is inducible and dependent on the state of activation and polarization of macrophages.7,8 Furthermore, the glucose levels in the plaque tissue may not necessarily reflect circulating glucose levels, as several factors might affect the local glucose concentration (e.g. plaque size), factors affecting the diffusion of glucose (e.g. endothelial permeability and neovessel density), and parameters modulating glucose metabolism (e.g. numbers of cells in the plaque and state of activation).7,8

Conclusions

In conclusion, we show that IRF5 expression is linked to symptoms and features of plaque vulnerability in human carotid endarterectomies in the CPIP biobank. Using a murine model of inducible carotid artery plaque rupture, we show that IRF5 drives not only the formation of morphologically vulnerable plaque, but also their actual rupture. We also demonstrate that the role of IRF5 in murine and human plaque instability is inextricably linked to the generation of IRF5+CD11c+ pro-inflammatory macrophages. Our study progresses our knowledge on IRF5 in atherosclerosis towards translation by offering validation of IRF5 as a potential therapeutic target in human CVD.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgements

We are grateful for the technical support of Lena Sundius and Morsal Zare.

Funding

This work was supported by the British Heart Foundation BHF Grant PG/18/1/33430 to C.M., the Swedish Society for Medical Research (516-0100) to A.E., Emil and Wera Cornell foundation to A.E., the Swedish Research Council (2019-01907 to A.E., 2019-01260 to I.G.), Crafoord foundation (20210796) to A.E., the Swedish Society of Medicine (SLS-961085) to A.E., the Swedish Heart and Lung Foundation (20200504 to A.E., 20200403 to I.G.), the SUS foundations and funds to A.E. and I.G., and the Lund University Diabetes Center (Swedish Research Council—Strategic Research Area Exodiab Dnr 2009-1039, Linnaeus grant Dnr 349-2006-23, the Swedish Foundation for Strategic Research Dnr IRC15-006), and the Novo Nordisk Foundation [grant number NNFI15CC0018346, NNF0064142] to C.M. The Knut and Alice Wallenberg foundation, the Medical Faculty at Lund University, and Region Skåne are acknowledged for generous financial support to A.E.

Conflict of interest: the authors have no competing interests to disclose.
References

1. Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276–1282.

2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–1695.

3. Naghavi M, Libby P, Virmani R. Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852–1866.

4. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2013;114:653–667.

5. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 deficiency impairs efferocytosis. Circ Res 2010;107:1150–1156.

6. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. IRF5:RelA interaction targets inflammatory genes in macrophages. Cell Rep 2014;8:1308–1317.

7. Seneviratne AN, Edsfeldt A, Cole JE, Kassiteridi C, Swart M, Park I, et al. IRF5 deficiency stabilizes atherosclerotic plaques in ApoE−/−mice. Eur Heart J 2020;41:ehaa946.3748.

8. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 deficiency impairs efferocytosis. Circ Res 2010;107:1150–1156.

9. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 deficiency impairs efferocytosis. Circ Res 2010;107:1150–1156.

10. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 deficiency impairs efferocytosis. Circ Res 2010;107:1150–1156.